Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by FarmerBetsyon Aug 21, 2023 6:20pm
158 Views
Post# 35598829

RE:RE:And there you have it.

RE:RE:And there you have it. They've been misleading retail investors for along time sad to say. A point last year with PMN 310 when Joann Kaplan annouced at the Alzheimers conference in July/22 that the company would be filing the IND in the 4th quarter/2022. We know how that went delay, delay, why didn't they do a  financing back in May if they were serious about going into the clinic at a much higher share price. It can't be more obvious what they have done over the last 4 months, starting Apr 28th when the stock was gaining momentum. Taking the stock down to an all time low since 2007,2008 from a high of $8.95 a month ago to today's price does everyone now agree that the Boston fix is in. I'm sure the same Boston group players are getting 95% of this placement. This won't last them long as the have at the end of June 8 million in unpaid bills on the balance sheet A/P. The boldness of what they have just done! 
<< Previous
Bullboard Posts
Next >>